
CJC-1295 No DAC 5mg
Studied for growth-axis and performance research.
CJC-1295 is a growth-hormone-releasing hormone (GHRH) analog engineered for extended stability. Two variants dominate the research literature: CJC-1295 "No DAC" — a shorter-acting GHRH analog — and CJC-1295 "with DAC" — which includes a Drug Affinity Complex that binds albumin and dramatically extends circulating half-life.
Proposed mechanism
Both variants bind the GHRH receptor in the anterior pituitary, stimulating growth-hormone release. The "with DAC" version carries a lysine-reactive maleimide linker that covalently binds serum albumin, extending half-life from hours (No DAC) to days (with DAC).
Research highlights
- Two research variants: No DAC (short-acting) and with DAC (long-acting)
- GHRH analog — different receptor than ghrelin-pathway secretagogues
- Frequently paired with ipamorelin for dual-pathway GH research
- Well-documented pharmacokinetic profiles in both variants
Research protocol notes
No DAC protocols typically use multi-daily dosing to match natural GH pulsatility. With DAC protocols use once-weekly schedules due to the extended half-life. Reconstitute in BAC water and aliquot.
Stacking and comparative studies
CJC-1295 + Ipamorelin is the standard dual-pathway GH research combination. Tesamorelin is an alternative GHRH-analog for researchers who prefer not to work with DAC-linked compounds.
Handling and storage
Lyophilized powder is stable at ambient shipping temperatures. Once reconstituted with bacteriostatic water, store at 2–8 °C and use within 28 days. For long-term storage of unreconstituted vials, freeze at −20 °C and protect from light.
Frequently asked
What does "DAC" mean?
Drug Affinity Complex — a chemical modification that allows the peptide to covalently bind serum albumin, extending its circulating half-life from hours to days.
Should I choose DAC or No DAC?
Depends on protocol design. No DAC is used when mimicking natural pulsatile GH release; with DAC is used for sustained-level research where weekly dosing is preferable.
How does it differ from ipamorelin?
CJC-1295 is a GHRH analog. Ipamorelin is a ghrelin-receptor agonist. They work on different receptors and are often combined.
Is it stable long-term?
Unreconstituted vials are stable at −20 °C for extended periods. Reconstituted solutions follow standard peptide handling — 2–8 °C, 28 days.



